Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-27
1998-10-27
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31355
Patent
active
058278788
ABSTRACT:
9-Cis-retinoic acid-.alpha.-tocopherol esters, pharmaceutical compositions containing the same and use of the same as a medicine for the treatment of leukemia, in particular, the remission of leukemia are provided and a combined use of a 9-cis-retinoic acid-.alpha.-tocopherol ester and either 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid exhibits a synergistic effect in the treatment of leukemia without any side effects caused by 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid.
REFERENCES:
patent: 3878202 (1975-04-01), Fukawa et al.
Makoto Makishima, et al., Blood, vol. 87, No. 8, pp. 3384-3394, "Enhancement of Activity of 1.alpha., 25-Dihydroxyvitamin D.sub.3 for Growth Inhibition and Differentiation Induction of Human Myelomonocytic Leukemia Cells by Tretinoin Tocoferil an .alpha.-Tocopherol Ester of All-Tans Retinoic Acid".
A. Verstuyf, et al., Proc. Workshop Vitamin D, vol. 9, No. Vitamin D, pp. 449-450, 1994, "Terminal Differentiation of Human Leukimia Cells (HL60) by a Combinbation of 1,25-Dihydroxyvitamin D.sub.3 and Retnoic Acid (All Trans or 9-Cis)".
Database WPI, Derwent Publication, AN 92-337748, JP 04-244076, Sep. 1, 1992.
M. Lanotte, et al., "NB4, A Maturation Inducible Cell Line with t(15;17) Marker Isolated from a Human Acute Promyelocytic Leukemia (M3)", Blood, vol. 77, No. 5, Mar. 1, 1991: pp. 1080-1086.
Raymond P.Warrell, Jr.,et al., "Acute Promyelocytic Leukemia", The New England Journal of Medicine, vol. 329, No. 3, Jul. 15, 1993, pp. 177-189.
Martin Petkovich, et al., "A Human Retinoic Acid Receptor Which Belongs to the Family of Nuclear Receptors", Nature, vol. 330, Dec. 3, 1987, pp. 444-450.
Akiko Sakashita, et al., "9-Cis-Retinoic Acid: Effects on Normal and Leukemic Hematopoiesis in Vitro", Blood, vol. 81, No. 4, Feb. 15, 1993: pp. 1009-1016.
Vincent Giguere, et al., Identification of a Receptor for the Morphogen Retinoic Acid, Nature, vol. 330, Dec. 17, 1987: pp. 624-629.
H. Phillip Koeffler, et al., 1,25-Dihydroxyvitamin D3: In Vivo and In Vitro Effects on Human Preleukemic and Leukemic Cells, Cancer Treatment Reports, vol. 69, No. 12, Dec. 1985, 1399-1407.
Daniel D. Bikle, "Clinical Counterpoint: Vitamin D: New Actions, New Analogs, New Therapeutic Potential", Endocrine Reviews, vol. 13, No. 4, pp. 765-784.
Raymond P. Warrell, Jr. "Retinoid Resistance in Acute Promyelocytic Leukemia: New Mechanisms, Strategies, and Implications", Blood, vol. 82, No. 7, Oct. 1, 1993: pp. 1949-1953.
Richard A. Heyman, et al., "9-Cis Retinoic Acid is a High Affinity Ligand for the Retinoid X Receptor", Cell, vol. 68, Jan. 24, 1992, pp. 397-406.
M. Makishima, et al., International Journal of Hematology, Supplement No. 1, Apr. 1997, vol. 65, p. 41, "Differentiation Therapy with Novel Retinoid Analogs" Translated part only.
Honma Yoshio
Inomata Kohei
Kanatani Yasuhiro
Kishiye Takao
Makishima Makoto
Goldberg Jerome D.
Nisshin Flour Milling Co. Ltd.
LandOfFree
Pharmaceutical composition for the treatment of leukemia contain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for the treatment of leukemia contain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the treatment of leukemia contain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1614191